A phase I clinical trial with OncoVEXGM-CSF

被引：0
|
作者：
Hu, J
McNeish, I
Shorrock, C
Steiner, J
Love, C
Coffin, R
Coombes, C
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] BioVex Ltd, Abingdon, Oxon, England
[3] Oxford Therapeut Consulting, Oxford, England
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1160
引用
收藏
页码：S447 / S447
页数：1
相关论文
共 50 条
  • [1] 肿瘤疫苗OncoVEXGM-CSF
    赵玉娜
    邢爱敏
    药学进展, 2011, 35 (05) : 236 - 237
  • [2] Results of a phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus.
    Coffin, RS
    Hu, JC
    Davis, CJ
    James, ND
    Love, C
    Michael, A
    Pandha, H
    Steiner, J
    Steven, NM
    Coombes, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 216S - 216S
  • [3] ONCOVEXGM-CSF Armed Oncolytic Virus
    Senzer, Neil
    Bedell, Cynthia
    Nemunaitls, John
    DRUGS OF THE FUTURE, 2010, 35 (06) : 449 - 455
  • [4] Phase I/II trial of OncoVEXGM-CSF combined with radical chemoradiation (CRT) in patients with newly diagnosed node-positive stage III/IV head and neck cancer (HNC)
    Coffin, R. S.
    Hingorani, M.
    McNeish, I.
    Sibtain, A.
    Hamilton, B.
    Love, C.
    Nutting, C.
    Harrington, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
    Hu, Jennifer C. C.
    Coffin, Robert S.
    Davis, Ceri J.
    Graham, Nicola J.
    Groves, Natasha
    Guest, Peter J.
    Harrington, Kevin J.
    James, Nicholas D.
    Love, Colin A.
    McNeish, Iain
    Medley, Louise C.
    Michael, Agnieszka
    Nutting, Christopher M.
    Pandha, Hardev S.
    Shorrock, Claire A.
    Simpson, Julie
    Steiner, Jan
    Steven, Neil M.
    Wright, Dennis
    Coombes, R. Charles
    CLINICAL CANCER RESEARCH, 2006, 12 (22) : 6737 - 6747
  • [6] Phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)
    Harrington, K.
    Hingorani, M.
    Tanay, M.
    Matthews, J.
    Newbold, K.
    Renouf, L.
    Coffin, R. S.
    McNeish, I.
    Nutting, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] 溶瘤病毒OncoVexGM-CSF在恶性肿瘤中的应用及研究进展
    柯雪
    董武
    白枫
    杨琨
    中国全科医学, 2014, 17 (08) : 960 - 963
  • [8] Phase I clinical and pharmacokinetic trial of irofulven
    James P. Thomas
    Rhoda Arzoomanian
    Dona Alberti
    Chris Feierabend
    Kimberly Binger
    Kendra D. Tutsch
    Thomas Steele
    Rebecca Marnocha
    Charlotte Smith
    Sheri Smith
    John MacDonald
    George Wilding
    Howard Bailey
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 467 - 472
  • [9] Towards a Phase I Clinical Trial for Cystinosis
    Lobry, Tatiana
    Sharma, Jay
    Ur, Sarah
    Lau, Athena
    Rocca, Celine
    Kohn, Donald B.
    Carbonaro, Denise
    Hernandez, Laura
    Cherqui, Stephanie
    MOLECULAR THERAPY, 2016, 24 : S14 - S15
  • [10] Phase I clinical and pharmacokinetic trial of irofulven
    Thomas, JP
    Arzoomanian, R
    Alberti, D
    Feierabend, C
    Binger, K
    Tutsch, KD
    Steele, T
    Marnocha, R
    Smith, C
    Smith, S
    MacDonald, J
    Wilding, G
    Bailey, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (06) : 467 - 472
12345